Searched for
CHANDAVARKAR
Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
- Biocon Biologics provided 7,000 doses of Itolizumab in AprilThe company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new...
- Biocon Biologics promotes Shreehas Tambe as deputy CEOA Biocon veteran, Shreehas Tambe joined the company in 1997 and has more than 20 years of leadership experience in operational and strategi...
- Biocon reports 64% jump in Q4 net riding on biologicsBiocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
- Adjudication is no substitute to poor policy and ineffectual governmentMany are now asking that age old question - has the court overstepped its limits and engaged in ‘judicial overreach’? The answer to this is...
- Buy Biocon, target Rs 668: Kunal BothraBuy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.
- Buy Biocon, target Rs 642: Jay ThakkarBuy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.
- Biocon introduces oncologic biosimilar KRABEVA in IndiaThe biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...
- Buy FDC, target Rs 200: Ruchit JainBuy FDC at a price target of Rs 200 and a stop loss at Rs 176 from entry point.
- See full recovery from GST impact in second half of 2017: Arun Chandavarkar, BioconIn order to recover in terms of to compensate or offset these costs through revenues in Malaysia we had guided that as and when initially w...
- Buy Biocon Ltd. target Rs 1234.0 : Rakesh BansalBuy Biocon Ltd. at a price target of Rs 1234.0 and a stoploss at Rs 1107.0 from entry point
- Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumabThe submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokin...
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
- Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progressBiocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...
- All actions will be well within the Constitution, says new UP Governor Ram NaikWhatever action I take or whatever I will do, will be within the Laxman rekha of the Constitution, says new UP Governor Ram Naik
- Biocon posts 15% rise in revenue, names new CEOBiocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at...
- Biocon Q4 Net dips 54 per cent at Rs 113 croreFor the year ended March 31, 2014, the company's net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-...
- FDC promoters plan to sell 67% stake; stock hits 52-week highFDC surged over 14% to hit a 52-week high of Rs 105.95 on reports that the promoters of the pharma firm, plan to sell their 67% stake in th...
- Biocon joins hands with US co Amylin for diabetes drugBiocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals.
Load More
